Pazopanib

For research use only.

Catalog No.S3012 Synonyms: GW786034

40 publications

Pazopanib Chemical Structure

Molecular Weight(MW): 437.52

Pazopanib is a novel multi-target inhibitor of VEGFR1, VEGFR2, VEGFR3, PDGFR, FGFR, c-Kit and c-Fms with IC50 of 10 nM, 30 nM, 47 nM, 84 nM, 74 nM, 140 nM and 146 nM in cell-free assays, respectively.

Size Price Stock Quantity  
USD 70 In stock
USD 210 In stock
Bulk Discount

Free Overnight Delivery on orders over $ 500
Next day delivery by 10:00 a.m. Order now.

Selleck's Pazopanib has been cited by 40 publications

Purity & Quality Control

Choose Selective VEGFR Inhibitors

Biological Activity

Description Pazopanib is a novel multi-target inhibitor of VEGFR1, VEGFR2, VEGFR3, PDGFR, FGFR, c-Kit and c-Fms with IC50 of 10 nM, 30 nM, 47 nM, 84 nM, 74 nM, 140 nM and 146 nM in cell-free assays, respectively.
Targets
VEGFR1 [1]
(Cell-free assay)
VEGFR2 [1]
(Cell-free assay)
VEGFR3 [1]
(Cell-free assay)
c-Kit [1]
(Cell-free assay)
PDGFR [1]
(Cell-free assay)
10 nM 30 nM 47 nM 74 nM 84 nM
In vitro

Pazopanib potently inhibits VEGF-induced phosphorylation of VEGFR2 in HUVEC cells with IC50 of 8 nM. [1] PPazopanib shows dose-dependent growth inhibition in all synovial sarcoma cell lines including SYO-1 and HS-SY-II cells. Proliferation of SYO-1 and HS-SY-II cells is inhibited even at 1 µg/mL of Pazopanib and is completely abolished at 5 µg/mL. Pazopanib induces G1 arrest, and thereby suppresses the growth of synovial sarcoma cells. Phosphorylation of Akts, GSK-3β, JNKs, p70 S6 Kinase, and mTOR is suppressed in Pazopanib-treated SYO-1 cells compared with that in the vehicle-treated cells. [2] Pazopanib between 20 m g/mL and 22.5 m g/mL shows an increasing reduction of RPE cell viability. [3]

Cell Data
Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID
human EoL-1-cell cell MVXHdo94fGhiaX7obYJqfGmxbjDhd5NigQ>? M{PrR2lvcGmkaYTpc44hd2ZiaIXtZY4hTW:OLUGtZ4VtdCClZXzsJIdzd3e2aDDpckBiKGOnbHygeoli[mmuaYT5JIF{e2G7LDDpZ|UxRTJwOEnlMVA2KM7:TR?= MnTXV2FPT0WU
human AN3-CA cell MmrQS5Jwf3SqIHnubIljcXSrb36gZZN{[Xl? MkfmTY5pcWKrdHnvckBw\iCqdX3hckBCVjNvQ1GgZ4VtdCCpcn;3eIghcW5iYTDj[YxtKH[rYXLpcIl1gSCjc4PhfUwhUUN3ME2xNE4xPSCwTR?= M3njT3NCVkeHUh?=
human CGTH-W-1 cell NH;hVpFIem:5dHigbY5pcWKrdHnvckBie3OjeR?= M1\JdmlvcGmkaYTpc44hd2ZiaIXtZY4hS0eWSD3XMVEh[2WubDDndo94fGhiaX6gZUBk\WyuII\pZYJqdGm2eTDhd5NigSxiSVO1NF01OC5yMTDuUS=> M2rGW3NCVkeHUh?=
human GDM-1 cell MUfHdo94fGhiaX7obYJqfGmxbjDhd5NigQ>? NXG3R4M3UW6qaXLpeIlwdiCxZjDoeY1idiCJRF2tNUBk\WyuIHfyc5d1cCCrbjDhJINmdGxidnnhZoltcXS7IHHzd4F6NCCLQ{WwQVExOy57OTDuUS=> NULHVVZFW0GQR1XS
human A204 cell M2HI[mdzd3e2aDDpcohq[mm2aX;uJIF{e2G7 MofPTY5pcWKrdHnvckBw\iCqdX3hckBCOjB2IHPlcIwh\3Kxd4ToJIlvKGFiY3XscEB3cWGkaXzpeJkh[XO|YYmsJGlEPTB;MUC5MlA3KG6P NXzyTlNPW0GQR1XS
human G-402 cell NXjYfpdHT3Kxd4ToJIlvcGmkaYTpc44h[XO|YYm= NVvi[XBNUW6qaXLpeIlwdiCxZjDoeY1idiCJLUSwNkBk\WyuIHfyc5d1cCCrbjDhJINmdGxidnnhZoltcXS7IHHzd4F6NCCLQ{WwQVU{OS56NDDuUS=> NXnqUFNNW0GQR1XS
human MFE-296 cell NVzhfWMxT3Kxd4ToJIlvcGmkaYTpc44h[XO|YYm= MXXJcohq[mm2aX;uJI9nKGi3bXHuJG1HTS1{OU[gZ4VtdCCpcn;3eIghcW5iYTDj[YxtKH[rYXLpcIl1gSCjc4PhfUwhUUN3ME2wMlU6ODJ{IN88US=> MWjTRW5ITVJ?
human NOS-1 cell M3f2UGdzd3e2aDDpcohq[mm2aX;uJIF{e2G7 Mnq3TY5pcWKrdHnvckBw\iCqdX3hckBPV1NvMTDj[YxtKGe{b4f0bEBqdiCjIHPlcIwhfmmjYnnsbZR6KGG|c3H5MEBq[zVyPUCuOlU6QDdizszN MkP1V2FPT0WU
human KG-1 cell MkjCS5Jwf3SqIHnubIljcXSrb36gZZN{[Xl? MofETY5pcWKrdHnvckBw\iCqdX3hckBMTy1zIHPlcIwh\3Kxd4ToJIlvKGFiY3XscEB3cWGkaXzpeJkh[XO|YYmsJGlEPTB;MD63NVc2PSEQvF2= Mm\LV2FPT0WU
human HT55 cell NILWfJlIem:5dHigbY5pcWKrdHnvckBie3OjeR?= MmrpTY5pcWKrdHnvckBw\iCqdX3hckBJXDV3IHPlcIwh\3Kxd4ToJIlvKGFiY3XscEB3cWGkaXzpeJkh[XO|YYmsJGlEPTB;MD65PFc5OSEQvF2= MW\TRW5ITVJ?
human MG-63 cell NXfofGFFT3Kxd4ToJIlvcGmkaYTpc44h[XO|YYm= Mmr1TY5pcWKrdHnvckBw\iCqdX3hckBOTy14MzDj[YxtKGe{b4f0bEBqdiCjIHPlcIwhfmmjYnnsbZR6KGG|c3H5MEBKSzVyPUGuNFAyPDZizszN M2PwXXNCVkeHUh?=
human CCF-STTG1 cell MUjHdo94fGhiaX7obYJqfGmxbjDhd5NigQ>? NH;aUllKdmirYnn0bY9vKG:oIHj1cYFvKEOFRj3TWHRIOSClZXzsJIdzd3e2aDDpckBiKGOnbHygeoli[mmuaYT5JIF{e2G778{MJGlEPTB;MT6wOFk5OSEQvF2= NVXUT|JMW0GQR1XS
human RT-112 cell M{T3Nmdzd3e2aDDpcohq[mm2aX;uJIF{e2G7 M{fLUGlvcGmkaYTpc44hd2ZiaIXtZY4hWlRvMUGyJINmdGxiZ4Lve5RpKGmwIHGgZ4VtdCC4aXHibYxqfHliYYPzZZktKEmFNUC9NU4yODN5NjFOwG0> MX\TRW5ITVJ?
human MC-IXC cell M1zGcGdzd3e2aDDpcohq[mm2aX;uJIF{e2G7 M162SWlvcGmkaYTpc44hd2ZiaIXtZY4hVUNvSWjDJINmdGxiZ4Lve5RpKGmwIHGgZ4VtdCC4aXHibYxqfHliYYPzZZktKEmFNUC9NU4yOTVzMjFOwG0> NYLXO2V[W0GQR1XS
human HUTU-80 cell M4HLVGdzd3e2aDDpcohq[mm2aX;uJIF{e2G7 NXHjNWROUW6qaXLpeIlwdiCxZjDoeY1idiCKVWTVMVgxKGOnbHyg[5Jwf3SqIHnuJIEh[2WubDD2bYFjcWyrdImgZZN{[XluIFnDOVA:OS5{OEGwN{DPxE1? NGDy[2hUSU6JRWK=
human MV-4-11 cell NYXrb3h1T3Kxd4ToJIlvcGmkaYTpc44h[XO|YYm= MVXJcohq[mm2aX;uJI9nKGi3bXHuJG1XNTRvMUGgZ4VtdCCpcn;3eIghcW5iYTDj[YxtKH[rYXLpcIl1gSCjc4PhfUwhUUN3ME2xMlM1PTBzIN88US=> MWDTRW5ITVJ?
human LCLC-103H cell MlvHS5Jwf3SqIHnubIljcXSrb36gZZN{[Xl? MV;Jcohq[mm2aX;uJI9nKGi3bXHuJGxEVENvMUCzTEBk\WyuIHfyc5d1cCCrbjDhJINmdGxidnnhZoltcXS7IHHzd4F6 MlHHV2FPT0WU
human G-401 cell NYTmdlg2T3Kxd4ToJIlvcGmkaYTpc44h[XO|YYm= NWS5[pd{UW6qaXLpeIlwdiCxZjDoeY1idiCJLUSwNUBk\WyuIHfyc5d1cCCrbjDhJINmdGxidnnhZoltcXS7IHHzd4F6NCCLQ{WwQVEvPDZ2MkGg{txO M4nUO3NCVkeHUh?=
human A704 cell M{XyU2dzd3e2aDDpcohq[mm2aX;uJIF{e2G7 MUXJcohq[mm2aX;uJI9nKGi3bXHuJGE4ODRiY3XscEBoem:5dHigbY4h[SClZXzsJJZq[WKrbHn0fUBie3OjeTygTWM2OD1zLk[wN|I{KM7:TR?= MX3TRW5ITVJ?
human ESS-1 cell NXX4PHFRT3Kxd4ToJIlvcGmkaYTpc44h[XO|YYm= MYHJcohq[mm2aX;uJI9nKGi3bXHuJGVUWy1zIHPlcIwh\3Kxd4ToJIlvKGFiY3XscEB3cWGkaXzpeJkh[XO|YYmsJGlEPTB;MT62NFM6PiEQvF2= NYD3[XF6W0GQR1XS
human HLE cell MWjHdo94fGhiaX7obYJqfGmxbjDhd5NigQ>? M1;DOWlvcGmkaYTpc44hd2ZiaIXtZY4hUEyHIHPlcIwh\3Kxd4ToJIlvKGFiY3XscEB3cWGkaXzpeJkh[XO|YYmsJGlEPTB;MT62N|gxPCEQvF2= NULCVFhDW0GQR1XS
human NY cell MkjSS5Jwf3SqIHnubIljcXSrb36gZZN{[Xl? NYrDZoZZUW6qaXLpeIlwdiCxZjDoeY1idiCQWTDj[YxtKGe{b4f0bEBqdiCjIHPlcIwhfmmjYnnsbZR6KGG|c3H5MEBKSzVyPUGuPFQ5OjFizszN NVqwd2FwW0GQR1XS
human A427 cell M13ReWdzd3e2aDDpcohq[mm2aX;uJIF{e2G7 NHXJTnRKdmirYnn0bY9vKG:oIHj1cYFvKEF2MkegZ4VtdCCpcn;3eIghcW5iYTDj[YxtKH[rYXLpcIl1gSCjc4PhfUwhUUN3ME2xMlk5ODd3IN88US=> NH\TWWRUSU6JRWK=
human SK-N-DZ cell NEPy[ZNIem:5dHigbY5pcWKrdHnvckBie3OjeR?= NEPQ[WZKdmirYnn0bY9vKG:oIHj1cYFvKFONLV6tSHoh[2WubDDndo94fGhiaX6gZUBk\WyuII\pZYJqdGm2eTDhd5NigSxiSVO1NF0zNjB{M{ixJO69VQ>? NH3hb3NUSU6JRWK=
human J82 cell NVjkRWJvT3Kxd4ToJIlvcGmkaYTpc44h[XO|YYm= MXXJcohq[mm2aX;uJI9nKGi3bXHuJGo5OiClZXzsJIdzd3e2aDDpckBiKGOnbHygeoli[mmuaYT5JIF{e2G7LDDJR|UxRTJwME[wPFgh|ryP MkDWV2FPT0WU
human GI-1 cell MWrHdo94fGhiaX7obYJqfGmxbjDhd5NigQ>? M4GyWWlvcGmkaYTpc44hd2ZiaIXtZY4hT0lvMTDj[YxtKGe{b4f0bEBqdiCjIHPlcIwhfmmjYnnsbZR6KGG|c3H5MEBKSzVyPUKuNlI6PTFizszN NGnyco9USU6JRWK=
human NCI-H716 cell MU\Hdo94fGhiaX7obYJqfGmxbjDhd5NigQ>? NF\HfohKdmirYnn0bY9vKG:oIHj1cYFvKE6FST3IO|E3KGOnbHyg[5Jwf3SqIHnuJIEh[2WubDD2bYFjcWyrdImgZZN{[XluIFnDOVA:Oi5|MU[zN{DPxE1? M3PM[3NCVkeHUh?=
human SF126 cell M3vDemdzd3e2aDDpcohq[mm2aX;uJIF{e2G7 M4Hic2lvcGmkaYTpc44hd2ZiaIXtZY4hW0ZzMk[gZ4VtdCCpcn;3eIghcW5iYTDj[YxtKH[rYXLpcIl1gSCjc4PhfUwhUUN3ME2yMlQ4PDV7IN88US=> M3LocXNCVkeHUh?=
human H4 cell MoTMS5Jwf3SqIHnubIljcXSrb36gZZN{[Xl? MYfJcohq[mm2aX;uJI9nKGi3bXHuJGg1KGOnbHyg[5Jwf3SqIHnuJIEh[2WubDD2bYFjcWyrdImgZZN{[XluIFnDOVA:Oi53MUK2NkDPxE1? Mn\IV2FPT0WU
human LB831-BLC cell M2Xjc2dzd3e2aDDpcohq[mm2aX;uJIF{e2G7 NViwe4IxUW6qaXLpeIlwdiCxZjDoeY1idiCOQkizNU1DVENiY3XscEBoem:5dHigbY4h[SClZXzsJJZq[WKrbHn0fUBie3OjeTygTWM2OD1{LkW0OVY3KM7:TR?= NX75[WhTW0GQR1XS
human HCC1395 cell MYPHdo94fGhiaX7obYJqfGmxbjDhd5NigQ>? NHTVXZlKdmirYnn0bY9vKG:oIHj1cYFvKEiFQ{GzPVUh[2WubDDndo94fGhiaX6gZUBk\WyuII\pZYJqdGm2eTDhd5NigSxiSVO1NF0zNjV6MUW2JO69VQ>? NWXaVWpTW0GQR1XS
human LK-2 cell NHLiXFFIem:5dHigbY5pcWKrdHnvckBie3OjeR?= MWPJcohq[mm2aX;uJI9nKGi3bXHuJGxMNTJiY3XscEBoem:5dHigbY4h[SClZXzsJJZq[WKrbHn0fUBie3OjeTygTWM2OD1{Lk[0OVY6KM7:TR?= NH\RcZJUSU6JRWK=
human G-361 cell M{LDSGdzd3e2aDDpcohq[mm2aX;uJIF{e2G7 MnLLTY5pcWKrdHnvckBw\iCqdX3hckBINTN4MTDj[YxtKGe{b4f0bEBqdiCjIHPlcIwhfmmjYnnsbZR6KGG|c3H5MEBKSzVyPUOuNFQxQDJizszN M1XCbnNCVkeHUh?=
human NCI-H2342 cell M{P5cWdzd3e2aDDpcohq[mm2aX;uJIF{e2G7 MVvJcohq[mm2aX;uJI9nKGi3bXHuJG5EUS2KMkO0NkBk\WyuIHfyc5d1cCCrbjDhJINmdGxidnnhZoltcXS7IHHzd4F6NiCLQ{WwQVMvOTN|MU[g{txO Mm\OV2FPT0WU
human SK-LU-1 cell  NFfvdVNIem:5dHigbY5pcWKrdHnvckBie3OjeR?= NVHySYxvUW6qaXLpeIlwdiCxZjDoeY1idiCVSz3MWU0yKGOnbHyg[5Jwf3SqIHnuJIEh[2WubDD2bYFjcWyrdImgZZN{[XluIFnDOVA:Oy5zOEe2O{DPxE1? MlXuV2FPT0WU
human IGROV-1 cell  Mo\ZS5Jwf3SqIHnubIljcXSrb36gZZN{[Xl? NVXFfXRGUW6qaXLpeIlwdiCxZjDoeY1idiCLR2LPWk0yKGOnbHyg[5Jwf3SqIHnuJIEh[2WubDD2bYFjcWyrdImgZZN{[XluIFnDOVA:Oy5{NEexN{DPxE1? M{\USHNCVkeHUh?=
human EB2 cell M4jSNWdzd3e2aDDpcohq[mm2aX;uJIF{e2G7 NYDSSIJ3UW6qaXLpeIlwdiCxZjDoeY1idiCHQkKgZ4VtdCCpcn;3eIghcW5iYTDj[YxtKH[rYXLpcIl1gSCjc4PhfUwhUUN3ME2zMlI5OTZ6IN88US=> NHzwVZJUSU6JRWK=
human CAL-54 cell MVjHdo94fGhiaX7obYJqfGmxbjDhd5NigQ>? NIDPOI5KdmirYnn0bY9vKG:oIHj1cYFvKEODTD21OEBk\WyuIHfyc5d1cCCrbjDhJINmdGxidnnhZoltcXS7IHHzd4F6NCCLQ{WwQVMvOjh|Nkeg{txO MljmV2FPT0WU
human LB1047-RCC cell MY\Hdo94fGhiaX7obYJqfGmxbjDhd5NigQ>? MVzJcohq[mm2aX;uJI9nKGi3bXHuJG9EXUJvTTDj[YxtKGe{b4f0bEBqdiCjIHPlcIwhfmmjYnnsbZR6KGG|c3H5MEBKSzVyPUOuN|MyOzZ6IN88US=> Ml\HV2FPT0WU
Daudi cell Mny0S5Jwf3SqIHnubIljcXSrb36gZZN{[Xl? MnfPTY5pcWKrdHnvckBw\iCqdX3hckBNSjFyNEetVmNEKGOnbHyg[5Jwf3SqIHnuJIEh[2WubDD2bYFjcWyrdImgZZN{[XluIFnDOVA:Oy53M{G2OEDPxE1? M3;0UnNCVkeHUh?=
human Daudi cell NFH2eYtIem:5dHigbY5pcWKrdHnvckBie3OjeR?= MkjHTY5pcWKrdHnvckBw\iCqdX3hckBF[XWmaTDj[YxtKGe{b4f0bEBqdiCjIHPlcIwhfmmjYnnsbZR6KGG|c3H5MEBKSzVyPUOuOlYzOTlizszN NYn2[m9pW0GQR1XS
human A172 cell MUfHdo94fGhiaX7obYJqfGmxbjDhd5NigQ>? NVLHbJBGUW6qaXLpeIlwdiCxZjDoeY1idiCDMUeyJINmdGxiZ4Lve5RpKGmwIHGgZ4VtdCC4aXHibYxqfHliYYPzZZktKEmFNUC9N{44Ozd7IN88US=> NXLI[mV[W0GQR1XS
human KGN cell MWHHdo94fGhiaX7obYJqfGmxbjDhd5NigQ>? MmnaTY5pcWKrdHnvckBw\iCqdX3hckBMT05iY3XscEBoem:5dHigbY4h[SClZXzsJJZq[WKrbHn0fUBie3OjeTygTWM2OD12LkC2O|A6KM7:TR?= MX\TRW5ITVJ?
human SNG-M cell NXXNfYE3T3Kxd4ToJIlvcGmkaYTpc44h[XO|YYm= MnPVTY5pcWKrdHnvckBw\iCqdX3hckBUVkdvTTDj[YxtKGe{b4f0bEBqdiCjIHPlcIwhfmmjYnnsbZR6KGG|c3H5MEBKSzVyPUSuNFg3PjlizszN MnyyV2FPT0WU
human SW1710 cell M2O0cGdzd3e2aDDpcohq[mm2aX;uJIF{e2G7 NYD6Nos2UW6qaXLpeIlwdiCxZjDoeY1idiCVV{G3NVAh[2WubDDndo94fGhiaX6gZUBk\WyuII\pZYJqdGm2eTDhd5NigSxiSVO1NF01NjR5M{G4JO69VQ>? NGPZcY9USU6JRWK=
human HT29 cells NGLrSmxRem:uaX\ldoF1cW:wIHHzd4F6 MVzBcpRqeHKxbHnm[ZJifGm4ZTDhZ5Rqfmm2eTDh[4FqdnO2IHj1cYFvKEiWMkmgZ4VtdHNiaX6gd4VzfW1iY3;ueIFqdmmwZzDt[YRqfW1? MYqxPFYzODN6Mh?=
human A375P cells Mn\IVJJwdGmoZYLheIlwdiCjc4PhfS=> NFfZWmtCdnSrcILvcIln\XKjdHn2[UBi[3Srdnn0fUBi\2GrboP0JIh2dWGwIFGzO|VRKGOnbHzzJIlvKHOncoXtJINwdnSjaX7pcochdWWmaYXt Mnz6NVg3OjB|OEK=
human HN5 cells NHLFfVRRem:uaX\ldoF1cW:wIHHzd4F6 MoH2RY51cXC{b3zp[oVz[XSrdnWgZYN1cX[rdImgZYdicW6|dDDoeY1idiCKTkWgZ4VtdHNiaX6gd4VzfW1iY3;ueIFqdmmwZzDt[YRqfW1? MoW2NVg3OjB|OEK=
HUVEC NWfGZ2RUTnWwY4Tpc44h[XO|YYm= M1vDVlEh|ryP NFPhfI03KGh? NFzO[oVCdnSrYX7nbY9o\W6rYzDhZ5Rqfmm2eTDpckBJXV[HQzDhd5Nme3OnZDDhd{BqdmirYnn0bY9vKG:oIIT1ZoUh\m:{bXH0bY9vKGG2IECuNUB2VSCjZoTldkA3KGi{czDifUBO[XS{aXflcEBie3OjeR?= NHTNZmkzPDB|NkC0Ni=>
human Daoy cell M1jmRWdzd3e2aDDpcohq[mm2aX;uJIF{e2G7 MojsTY5pcWKrdHnvckBw\iCqdX3hckBF[W:7IHPlcIwh\3Kxd4ToJIlvKGFiY3XscEB3cWGkaXzpeJkh[XO|YYmsJGlEPTB;ND63O|k1QSEQvF2= M3ezdXNCVkeHUh?=
human DMS-273 cell MXrHdo94fGhiaX7obYJqfGmxbjDhd5NigQ>? MnTCTY5pcWKrdHnvckBw\iCqdX3hckBFVVNvMkezJINmdGxiZ4Lve5RpKGmwIHGgZ4VtdCC4aXHibYxqfHliYYPzZZktKEmFNUC9OE46PjJyMjFOwG0> NWLsZll7W0GQR1XS
human KU812 cell M4izdmdzd3e2aDDpcohq[mm2aX;uJIF{e2G7 Mln3TY5pcWKrdHnvckBw\iCqdX3hckBMXThzMjDj[YxtKGe{b4f0bEBqdiCjIHPlcIwhfmmjYnnsbZR6KGG|c3H5MEBKSzVyPUWuN|c5OTJizszN NUj5cVBEW0GQR1XS
human NCI-H727 cell NVS0THR{T3Kxd4ToJIlvcGmkaYTpc44h[XO|YYm= NHLrWpVKdmirYnn0bY9vKG:oIHj1cYFvKE6FST3IO|I4KGOnbHyg[5Jwf3SqIHnuJIEh[2WubDD2bYFjcWyrdImgZZN{[XluIFnDOVA:PS52MEmwNUDPxE1? MX7TRW5ITVJ?
human P30-OHK cell M4H3Z2dzd3e2aDDpcohq[mm2aX;uJIF{e2G7 MmXVTY5pcWKrdHnvckBw\iCqdX3hckBROzBvT1jLJINmdGxiZ4Lve5RpKGmwIHGgZ4VtdCC4aXHibYxqfHliYYPzZZktKEmFNUC9OU41Pjl2IN88US=> M3T5enNCVkeHUh?=
human MIA-PaCa-2 cell NVPhdI52T3Kxd4ToJIlvcGmkaYTpc44h[XO|YYm= MlLLTY5pcWKrdHnvckBw\iCqdX3hckBOUUFvUHHDZU0zKGOnbHyg[5Jwf3SqIHnuJIEh[2WubDD2bYFjcWyrdImgZZN{[XluIFnDOVA:PS54MES2OkDPxE1? NIe0N5NUSU6JRWK=
human TT cell MmLKS5Jwf3SqIHnubIljcXSrb36gZZN{[Xl? NVr0T5ZuUW6qaXLpeIlwdiCxZjDoeY1idiCWVDDj[YxtKGe{b4f0bEBqdiCjIHPlcIwhfmmjYnnsbZR6KGG|c3H5MEBKSzVyPUWuOlYzPCEQvF2= NXfPV4tuW0GQR1XS
human DK-MG cell MWfHdo94fGhiaX7obYJqfGmxbjDhd5NigQ>? MnvvTY5pcWKrdHnvckBw\iCqdX3hckBFUy2PRzDj[YxtKGe{b4f0bEBqdiCjIHPlcIwhfmmjYnnsbZR6KGG|c3H5MEBKSzVyPUWuO|IxOjhizqzt NFTaPZNUSU6JRWK=

... Click to View More Cell Line Experimental Data

Assay
Methods Test Index PMID
Western blot
p53 / PUMA ; 

PubMed: 27924057     


The expression of p53 or PUMA by western blotting analysis in HCT-116 cells treated with (left) 20 μM pazopanib for indicated hours or (right) with 1-20 μM pazopanib for 24 hours.

p-Akt / Akt ; 

PubMed: 27924057     


Akt is inhibited after pazopanib treatment in colon cells. The expression of P-Akt (S473) was detected by western blotting in (A) RKO or HT-29 cells after 20 μM pazopanib treatment for indicated times.

27924057
Growth inhibition assay
Cell viability; 

PubMed: 27924057     


Cell viability was analyzed using Cell Counting Kit-8 at 0, 3, 6, 12 and 24 hours after 1, 5, 10, or 20 μM pazopanib treatment in HCT-116 cells. Data represent the mean ± SEM of four independent experiments.

27924057
In vivo The mice treated with 30 mg/kg or 100 mg/kg Pazopanib reveals a significant decrease in tumor burden compared with the mice treated with vehicle or 10 mg/kg Pazopanib. Treatment with Pazopanib is well-tolerated and there is no significant difference in the body weight among the mice in each group. [2]

Protocol

Animal Research:

[2]

- Collapse
  • Animal Models: Immunodeficient mice bearing SYO-1 cells
  • Dosages: 0 mg/kg, 10 mg/kg, 30 mg/kg, or 100 mg/kg
  • Administration: Oral administration
    (Only for Reference)

Solubility (25°C)

In vitro DMSO 87 mg/mL warmed (198.84 mM)
Water Insoluble
Ethanol Insoluble

* Please note that Selleck tests the solubility of all compounds in-house, and the actual solubility may differ slightly from published values. This is normal and is due to slight batch-to-batch variations.

Chemical Information

Molecular Weight 437.52
Formula

C21H23N7O2S

CAS No. 444731-52-6
Storage powder
in solvent
Synonyms GW786034
Smiles C[N]1N=C2C=C(C=CC2=C1C)N(C)C3=NC(=NC=C3)NC4=CC=C(C)C(=C4)[S](N)(=O)=O

In vivo Formulation Calculator (Clear solution)

Step 1: Enter information below (Recommended: An additional animal making an allowance for loss during the experiment)
Dosage mg/kg Average weight of animals g Dosing volume per animal ul Number of animals
Step 2: Enter the in vivo formulation (Different batches have different solubility ratios, please contact Selleck to provide you with the correct ratio)
% DMSO % % Tween 80 % ddH2O
CalculateReset

Bio Calculators

Molarity Calculator

Molarity Calculator

Calculate the mass, volume or concentration required for a solution. The Selleck molarity calculator is based on the following equation:

Mass (mg) = Concentration (mM) × Volume (mL) × Molecular Weight (g/mol)

  • Mass
    Concentration
    Volume
    Molecular Weight

*When preparing stock solutions, please always use the batch-specific molecular weight of the product found on the via label and MSDS / COA (available on product pages).

Dilution Calculator

Dilution Calculator

Calculate the dilution required to prepare a stock solution. The Selleck dilution calculator is based on the following equation:

Concentration (start) x Volume (start) = Concentration (final) x Volume (final)

This equation is commonly abbreviated as: C1V1 = C2V2 ( Input Output )

  • C1
    V1
    C2
    V2

* When preparing stock solutions always use the batch-specific molecular weight of the product found on the vial label and MSDS / COA (available online).

The Serial Dilution Calculator Equation

  • Serial Dilutions

  • Computed Result

  • C1=C0/X C1: LOG(C1):
    C2=C1/X C2: LOG(C2):
    C3=C2/X C3: LOG(C3):
    C4=C3/X C4: LOG(C4):
    C5=C4/X C5: LOG(C5):
    C6=C5/X C6: LOG(C6):
    C7=C6/X C7: LOG(C7):
    C8=C7/X C8: LOG(C8):
Molecular Weight Calculator

Molecular Weight Calculator

Enter the chemical formula of a compound to calculate its molar mass and elemental composition:

Total Molecular Weight: g/mol

Tip: Chemical formula is case sensitive. C10H16N2O2 c10h16n2o2

Instructions to calculate molar mass (molecular weight) of a chemical compound:

To calculate molar mass of a chemical compound, please enter its chemical formula and click 'Calculate'.

Definitions of molecular mass, molecular weight, molar mass and molar weight:

Molecular mass (molecular weight) is the mass of one molecule of a substance and is expressed in the unified atomic mass units (u). (1 u is equal to 1/12 the mass of one atom of carbon-12)
Molar mass (molar weight) is the mass of one mole of a substance and is expressed in g/mol.

Molarity Calculator

Mass Concentration Volume Molecular Weight

Clinical Trial Information

NCT Number Recruitment interventions Conditions Sponsor/Collaborators Start Date Phases
NCT03735758 Recruiting Drug: pazopanib or guideline conform chemotherapy Soft Tissue Sarcoma Adult GWT-TUD GmbH November 2 2018 Phase 4
NCT03334409 Recruiting Drug: Ascorbic Acid|Drug: Pazopanib Hydrochloride Clear Cell Renal Cell Carcinoma|Metastatic Clear Cell Renal Cell Carcinoma|Stage III Renal Cell Cancer AJCC v8|Stage IV Renal Cell Cancer AJCC v7|Unresectable Renal Cell Carcinoma Academic and Community Cancer Research United|National Cancer Institute (NCI) February 16 2018 Phase 2
NCT03149120 Withdrawn Biological: Nivolumab|Drug: Pazopanib Soft Tissue Sarcomas NYU Langone Health|Bristol-Myers Squibb August 2017 Phase 2
NCT03091465 Completed -- Metastatic Renal Cell Carcinoma Spanish Oncology Genito-Urinary Group December 20 2016 --

Tech Support

Answers to questions you may have can be found in the inhibitor handling instructions. Topics include how to prepare stock solutions, how to store inhibitors, and issues that need special attention for cell-based assays and animal experiments.

Handling Instructions

Tel: +1-832-582-8158 Ext:3

If you have any other enquiries, please leave a message.

  • * Indicates a Required Field

VEGFR Signaling Pathway Map

Related VEGFR Products

Tags: buy Pazopanib | Pazopanib supplier | purchase Pazopanib | Pazopanib cost | Pazopanib manufacturer | order Pazopanib | Pazopanib distributor
×
Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID